Voyager Therapeutics Inc (NASDAQ: VYGR) has reported E.P.S. of $1.28 for its fourth fiscal quarter (ending December 31) versus $-0.61 for the same period a year ago. Relative to the consensus estimate of $-0.16, this was a premium of $1.44. For the latest four quarters through December 31, E.P.S. were $3.08 compared to $-1.21 a year ago.
Recent Price Action
On 2/28/24, Voyager Therapeutics Inc (NASDAQ: VYGR) stock rose modestly by 0.7%, closing at $8.97. Moreover, this advance was accompanied by above average trading volume at 129% of normal. Relative to the market the stock has been extremely weak over the last nine months but has risen 18.5% during the last week.
Current PriceTarget Research Rating
VYGR is expected to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Voyager Therapeutics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Voyager Therapeutics has a poor Power Rating of 30 and a very low Appreciation Score of 4, with the Lowest Value Trend Rating the result.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment